Peptide LibraryARA 290 (Cibinetide)
Also known as: PHβSP, Innate Repair Receptor agonist
ARA 290 (Cibinetide), also called PHβSP or Innate Repair Receptor agonist, is an innate Repair Receptor agonist. ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin.
For research use only.
Key Facts
- CAS
- 1208243-63-3
- Molecular Weight (MW)
- 1257.3 g/mol
- Half-life
- Short plasma half life (reported minutes; tissue protective signaling persists longer in models)
- FDA status
- Investigational New Drug (IND)
- FDA compounding lists
- 503A Category 3
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Innate repair receptor (EPOR–βc)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 27
- Listed offers
- 43
- Median price per mg (peptide vials)
- $4.90/mg
- Typical $4.67–$5.39/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials26 vendors · median $4.90/mg
- Sprays, route not stated1 vendor · $7.34/mg
Research summary
Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials2 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's ARA 290 (Cibinetide) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
ARA 290 (Cibinetide) dosage evidence
ARA 290 (cibinetide) has no approved dosage. Human dosing comes from phase 2 trials of daily injections under the skin for 28 days. In 64 people with sarcoidosis-related small nerve fiber loss, 1, 4 or 8 mg a day were compared with placebo, and only 4 mg significantly increased corneal nerve fiber area; a type 2 diabetes study used 4 mg a day.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1–8 mg once daily in phase 2 trials |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | 28 days in the published trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2b, sarcoidosis-associated small nerve fiber loss (NCT02039687)Clinical trial · Randomized, placebo-controlled phase 2b trial | Adults with sarcoidosis, small nerve fiber loss and neuropathic pain (n=64) | 1, 4 or 8 mg | Subcutaneous | Once daily | 28 days | Corneal nerve fiber area increased significantly with 4 mg only; pain improved in all groups | Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017. |
| Phase 2, type 2 diabetes with painful neuropathy (2015)Clinical trial · Randomized, placebo-controlled phase 2 trial | Adults with type 2 diabetes and painful neuropathy | 4 mg | Subcutaneous (self-administered) | Once daily | 28 days, followed for another month | Improved HbA1c, lipids and neuropathic symptom scores versus placebo | ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015. |
Where sources disagree
- The trials are small, phase 2 and 28 days long. Surrogate endpoints such as corneal nerve fiber area were the primary measures, and no phase 3 trial has been published.
- ARA 290 is engineered from erythropoietin but is designed not to stimulate red blood cell production; erythropoietin doses do not apply to it.
Reconstitution
Common research vial sizes: 10 mg, 16 mg, 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Reconstitute per supplier or clinical protocol instructions
- Injection Sites
- Abdomen (subQ)Thigh (subQ)
- Concentration Example
- Example only: 4 mg vial reconstituted with 2 mL = 2 mg/mL
- Expected Onset
- Tissue protective signaling observed in preclinical and early clinical studies
Sequence & molecular data
| Amino acid sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
|---|---|
| Molecular formula | C51H84N16O21 |
| Molecular weight | 1257.3 g/mol |
| CAS number | 1208243-63-3 |
| Half-life | Short plasma half life (reported minutes; tissue protective signaling persists longer in models) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 91810664 |
| FDA UNII | 9W5677JKDA |
| ChEMBL | CHEMBL3545305 |
| DrugBank | DB13006 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin. Erythropoietin has two distinct activities: haematopoiesis through the classical EPO receptor homodimer, and tissue protection through a separate heterodimeric innate repair receptor formed by EPOR paired with the beta common receptor CD131. ARA 290 was designed to engage only the second. It binds the innate repair receptor to trigger anti-inflammatory and cytoprotective signalling without stimulating erythropoiesis, avoiding the thrombotic and haematocrit effects that limit EPO itself. It has been studied in small-fibre neuropathy and sarcoidosis and is investigational.
Origin
Synthetic EPO helix-B peptide.
Targets
Studies
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- The time to develop treatments for diabetic neuropathy
- Managing fatigue in sarcoidosis - A systematic review of the evidence
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis
Research statistics
73 PubMed publications · 12.3% human clinical research · 4 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
ARA 290 (Cibinetide) has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
FDA compounding status
These FDA lists track substances nominated for use in pharmacy compounding. Being on a list is not FDA approval and doesn't mean a product is safe or effective.
| 503A Category 3 | Nominated without adequate support FDA source |
|---|
FDA list dated May 14, 2026.
How FDA approval, compounding and research-only status differ
Benefits
ARA 290 (Cibinetide) side effects
The effects below are those reported in ARA 290 (Cibinetide) clinical trials; long-term safety data may still be limited.
Side Effects
- Injection-site reactions
- Headache
- Trial-stage safety only
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
ARA 290 (Cibinetide): frequently asked questions
What is ARA 290 (Cibinetide)?
Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.
How does ARA 290 (Cibinetide) work?
ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin. Erythropoietin has two distinct activities: haematopoiesis through the classical EPO receptor homodimer, and tissue protection through a separate heterodimeric innate repair receptor formed by EPOR paired with the beta common receptor CD131.
Is ARA 290 (Cibinetide) FDA approved?
No. ARA 290 (Cibinetide) is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established. FDA's compounding lists show 503A Category 3: Nominated without adequate support.
What is the half-life of ARA 290 (Cibinetide)?
Reported half-life for ARA 290 (Cibinetide) is Short plasma half life (reported minutes; tissue protective signaling persists longer in models). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of ARA 290 (Cibinetide)?
ARA 290 (Cibinetide) has the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, giving a chain of 11 amino acids. Its molecular formula is C51H84N16O21.
What peptides are similar to ARA 290 (Cibinetide)?
Compounds most often compared with ARA 290 (Cibinetide) include Atosiban, B7-33, Carbetocin and Serelaxin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Invest Ophthalmol Vis Sci, 2017External reference
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Mol Med, 2015External reference
- The time to develop treatments for diabetic neuropathy — Expert Opin Investig Drugs, 2021External reference
- Managing fatigue in sarcoidosis - A systematic review of the evidence — Chron Respir Dis, 2017External reference
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis — Expert Opin Investig Drugs, 2014External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This ARA 290 (Cibinetide) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track ARA 290 (Cibinetide) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →